CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Drug Reimbursement Recommendation - tafamidis (Vyndaqel)

February 21, 2020
Today, CADTH has issued final recommendations for: tafamidis (Vyndaqel) Indications: transthyretin-mediated amyloidosis Recommendation: Reimburse with clinical criteria and/or conditions For more information

Call for Feedback: Rituximab to Treat Primary Membranous Nephropathy

February 13, 2020
A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders. Rituximab to Treat Primary Membranous Nephropathy Call for Feedback: 2020-02-13 Feedback Due By: 2020-02-28 Consultation Document: Proposed Project Scope Product Type: Health Technology Assessment Submit Feedback

New at CADTH — February 2020

February 10, 2020
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

CADTH Pharmaceutical Reviews Update — Issue 13

February 6, 2020
See Pharmaceutical Reviews Update – Issue 13 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include: New consolidated document for pCODR procedures and guidelines Clarifications regarding economic submission requirements Update for patients and communities